Number of biopharmaceuticals requiring technical reviews in China 2018-2021
In 2021, the Center for Drug Evaluation of the National Medical Products Administration (NMPA) in China received almost 2,000 applications for approval of biopharmaceuticals. The figure increased substantially from the previous years, and represented more than 20 percent of all applications received by the governing body. Examples of biopharmaceuticals include vaccines, blood products, and "living medicine" used in cell therapy.